|
1 Obta M，Inoue H, Cotticelli MG，et al. The FHIT gene, spanning the chromosome 3p14. 2fragile site and renal carcinoma-associated t(3∶ 8)breakpoint，is abnormal in digestive tract cancers. Cell, 1996, 84：587-597.
|
|
2 Barnes LD，Garrison PN，Siprashvili Z，et al. Fhit，a putative tumor suppressor in humans, is a dinucleoside 5'，5'-p1，p3-triphophate hydrolase. Biochem, 1996，35：11529-11536.
|
|
3 Matthews CP，Shera K，Kiviat N，et al. Expression of truncated FHIT transcripts in cervical cancers and in normal human cells. Oncogene, 2001,20:4665-4675.
|
|
4 Matsuyama A, Shiraishi T, Trapasso F，et al. Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2：evolutionarily conserved but highly recombinogenic. Proc Natl Acad Sci USA，2003,100(25):14988-14993.
|
|
5 Ji L, Fang B，Yen N. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad(FHIT)gene overexpression. Cancer Res，1999，59：3333-3339.
|
|
6 Roz L, Gramegna M，Ishii H, et al. Restoration of fragile histidine triad(FHIT)expression induces apoptosis andsuppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA, 2002，99：3615-3620.
|
|
7 Roz L, Andriani F, Ferreira CG, et al. The apoptotic pathway triggered by the FHIT protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-X(L)overexpression. Oncogene. 2004，23(56)：9102-9110.
|
|
8 Askari MD, Vo-Dinh T. Implication of mitochondrial involvement in apoptotic activity of fragile histidine triad gene：application of synchronous luminescence spectroscopy. Biopolymers，2004，73(4)：510-523.
|
|
9 Gopalakrishnan VK，Banerjee AG, Vishwanatha JK. Effect of FHIT gene replacement on growth，cell cycle and apoptosis in pancreatic cancer cells. Pancreato, 2003，3(4)：293-302.
|
|
10 Fujishita T，Doi Y，Sonoshita M, et al. Development of spontaneous tumors and intestinal lesions in FHIT gene knockout mice. Br J Cancer, 2004，91(8)：1571-1514.
|
|
11 Ishii H, Zanesi N，Vecchione A, et al. Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J，2003，17(12)：1768-1770.
|
|
12 Baykal C, Ayhan A, Al A, et al. No relationship is indicated between FHIT expression and clinicopathologic prognostic parameters in early stage cervical carcinoma. Int J Gynecolo Cancer. 2003，13：192-196.
|
|
13 Greenspan DL, Connolly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res,1997, 57:4692-4698.
|
|
14 Yoshino K, Enomoto T, Nakamura T, et al. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer, 1998，76：176-181.
|
|
15 Virmani AK, Muller C，Rathi A，et al. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res, 2001，7: 584-589.
|
|
16 Nakagawa S，Yoshikawa H, Kimura M，et al. A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cellcarcinoma of the uterine cervix. Br J Cancer，1999，79(3/4)：589-594.
|
|
17 ELhamidi A,Hamoudi RA，Kocjan G,et al. Cervical intraepithelial neoplasia：prognosis by combined LOH analysis of multiple loci . Gynecolo Oncolo，2004，94(3)：671-680.
|
|
18 Helland A, Kraggerud SM, Kristensen GB, et al. Primary cervical carcinomas show 2 common regions of deletion at 3P，1 within the FHIT gene：evaluation of allelic inbalance at FHIT，RB1 and TP53 in relation to survival. Int J Cancer, 2000，88：217-222.
|
|
19 Machida, Shizuo,Ohwada, et al. Abnormal Fragile Histidine Triad Expression in Advanced Cervical Cancer and Evaluation of Its Utility as a Prognostic Factor. Oncol, 2003，65(1),89-94.
|
|
20 Krivak TC，McBroom JW，Seidman J，et al. Abnormal fragile histidine triad(FHIT)expression in advanced cervical carcinoma：a poor prognostic factor. Cancer Res, 2001，61: 4382-4385.
|
|
21 Huang LW，Chao SL, Chen TJ. Reduced FHIT expression in cervical carcinoma：correlation with tumor progression and poor prognosis. Gynecolo Oncolo,2003, 90(2): 331-338.
|
|
22 Terry G, Ho L, Londesborough P，et al. The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions. Br J Cancer, 2004，91(12):2056-2062.
|
|
23 Jee SH, Um SJ, Lee JE, et al. The effect of codon 98 of the FHIT gene on cervical cancer in Korean women. Int J Gynecolo Cancer, 2003，13:843-848.
|
|
24 Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol, 1999, 17:1618-1624.
|
|
25 Baffa R，Veronese ML, Santoro R, et al. Loss of FHIT expression in gastric carcinoma. Cancer Res，1998，58: 4708-4714.
|
|
26 Breiburd F, Ramoz N, Salmon J, et al. HLA control in the progression of human papillomavirus infection. Semin Cancer Biol, 1996，7：359-371.
|
|
27 Sozzi G，Sard L，Degregorio L，et al. Loss of FHIT function in lung cancer and preinvasive bronchila lesions. Cancer Res. 1999，58：5032-5037.
|
|
28 Wu QH，Shi H，Suo ZH，et al. 5'-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinicalStage in cervical carcinomas. Ultrastr Patho，2003，27:417-422.
|
|
29 Kang S,Kim JW，Kang GH，et al. Polymorphism in folate-and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecolo Oncol，2005，96(1)：173-180.
|
|
30 Lea JS, Ashfaq R, Muneer S, et al. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. J Soci Gynecolo Invest, 2004，11(5)：329-338.
|
|
31 Yoshino K，Enomoto T，Nakamura T，et al. FHIT alterations in cancerous and noncancerous cervical epithelium. Int J Cancer, 2000，(85)：6-13.
|